Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients (Q37800176)

23 August 2017

title

Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients (English)

1 reference

23 August 2017

0 references

1 reference

Ana O Hoff

1

1 reference

23 August 2017

Bela Toth

2

1 reference

23 August 2017

Mimi Hu

3

1 reference

23 August 2017

Gabriel N Hortobagyi

4

1 reference

23 August 2017

Robert F Gagel

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

28 September 2010

1 reference

Annals of the New York Academy of Sciences

23 August 2017

published in

1 reference

23 August 2017

volume

1218

1 reference

23 August 2017

page(s)

47-54

1 reference

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients--a report of a thirty year retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05771.X

10.1111/J.1749-6632.2010.05771.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference